YCYasemin Benderli Cihan

Yasemin Benderli Cihan

*This is an algorithmically generated author record based on publicly available information.

Yasemin Benderli Cihan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of Radiotherapy in Ovarian Serous Carcinoma with Leptomeningeal Metastasis: A Case Report

    by Fatma Humeyra Ergun, Mehmet Yasin Erdem, Yasemin Benderli Cihan

    Ovarian cancer accounts for 4% of all cancers in women and very rarely metastasizes to the leptomeningeal region. Recent advances in systemic treatment options and the resulting increase in survival have led to an increase in central nervous system metastases. Radiotherapy plays a crucial role in the multidisciplinary management of leptomeningeal metastases. This study will discuss a case of serous ovarian carcinoma that presented to our clinic with leptomeningeal metastases two years after surgery and adjuvant chemotherapy, for which we administered palliative radiotherapy.

  • Open Access

    Primary Cutaneous B-cell Lymphoma with Widespread Involvement: Case Report

    by Mehmet Yasin Erdem, Yusuf Turker, Yasemin Benderli Cihan

    Primary cutaneous lymphomas (PCL) are extranodal non-Hodgkin lymphomas affecting the skin without other systemic involvement at the time of diagnosis. Our case was a 62-year-old patient with PCBLC who had deep and multiple skin involvement but no systemic symptoms or involvement. At diagnosis, there was widespread skin involvement of the anterior chest wall, more pronounced on the left side. The patient received RT at 30 Gy/17 fractions for the lesions located on the anterior chest wall and 20 Gy/11 fractions as a boost to the primary mass. Six months after treatment, the patient demonstrated a near-complete response. In this case report, a case of primary B-cell cutaneous lymphoma with widespread chest wall involvement, which achieved a complete response to RT, is discussed with the literature.

  • Open Access

    Diffuse Dural Thickening and Contrast Enhancement

    by Yusuf Turker, Mehmet Yasin Erdem, Yasemin Benderli Cihan

    Dural metastasis is a rare sign of advanced cancers, most often linked to breast, lung, and prostate cancers. With better survival rates in metastatic prostate cancer due to improvements in systemic treatment, unusual patterns like dural involvement are becoming more common. We present an unusual case of widespread dural metastasis from prostate adenocarcinoma that resulted in facial paralysis. A 69-year-old man with metastatic prostate cancer and extensive bone involvement came in with a headache and one-sided facial paralysis. A cranial MRI showed thickening of the dura and contrast enhancement affecting all dural surfaces. The patient received corticosteroids and palliative whole-brain radiotherapy, but he passed away from pneumonia three weeks later. This case emphasizes the need to consider dural metastasis in cancer patients who show unusual neurological symptoms. Early detection with cranial MRI is essential, and radiotherapy is an important option for palliative care. Reporting such rare cases helps improve awareness and guides clinical decisions.

  • Open Access

    The role of radiotherapy in familial, multiple and symptomatic cerebral cavernomas

    by Yasemin Benderli Cihan, Yusuf Türker, Şeyma Demir

    Stereotactic radiosurgery is an effective and safe method that can help prevent the development of deep-seated or large-sized cavernomas. However, there are limited studies on familial, multiple and symptomatic cerebral cavernous malformations (CCM). The approach in these cases is not yet clear. This case is a CCM that can be confused with other brain masses and metastases, and contributes to the literature in terms of genetic transmission, management and treatment of cavernomas.

  • The Relationship Between Pan-immune-inflammation Value and Survival in Breast Cancer Patients

    by Yasemin Benderli Cihan

    The aim of this study was to investigate the effect of pan-immune-inflammation value (PIV), one of the inflammation markers, on progression-free survival (PFS) and overall survival (OS) in patients diagnosed with breast cancer, and the factors affecting PFS and OS. The files of patients who received adjuvant treatment for breast cancer at the radiation oncology outpatient clinic of Kayseri Education and Research Hospital were retrospectively scanned. The relationship between PIV value and OS and PFS was investigated. Three hundred female patients who underwent modified radical mastectomy were included in the study. The average age was 55 years. Ninety-five percent of the patients received chemotherapy, 69.3% of the patients received radiotherapy, and 61.3% of the patients received hormonal therapy. The PIV cutoff value was determined as 278, and PIV was above 278 in 176 (58.6%) patients. When the chi-square test was performed for PIV values, it was seen that the menopause factor was effective. OS mean was 79.7 months and PFS mean was 79.2 months. Thirty-seven cases died due to disease or non-disease reasons. Local recurrence and/or distant metastasis was detected in 40 cases. Statistical significance was found between menopause status (p = 0.021). The factors that had a statistically significant effect in univariate and multivariate analysis were neutrophils (p = 0.004; OR, 1.1; CI, 1.0–1.2) and PIV value (p = 0.001; OR, 0.2; CI, 0.0–0.6). Those affecting PFS are neutrophil count (p = 0.018; OR, 1.1; CI, 1.0–1.2), PIV (p = 0.006; OR, 0.3; CI, 0.1–0.7), and monocyte PIV value (p = 0.025; OR, 01.8; CI, 1.0–3.1). High PIV value was found to be a poor prognostic factor in overall survival and disease-free survival in breast cancer patients who underwent modified radical mastectomy.

  • Open Access

    The effect of surgery and hormone therapy on quality of life in breast cancer patients receiving radiotherapy

    by Yasemin Benderli Cihan, Orhun Öztürk

    Objective: The aim of this study was to examine the effect of surgery type and hormone therapy on the general quality of life in breast cancer patients receiving radiotherapy. Material and Methods: A total of 109 patients were included in the study. As data collection tools in the research, a form stating the demographic and clinical features was used in the first part, and in the second part, “EORTC QLQ-C30” developed by the European Organization for Research and Treatment of Cancer and “EORTC QLQ-BR23” Turkish quality of life forms specific to breast cancer were used. The patients were asked to fill in the questionnaire forms on the first day, the last day of radiotherapy and three months after the end of the treatment. Results: Mean age of this study was 54.8 ± 12.1 years. In the questionnaires made on the first day, last day and three months after radiotherapy, the highest score according to the EORTC QLQ-C30 scale was in social and cognitive function, and in sexual life on the EORTC QLQ-BR23 scale. According to multiple comparison test and comparing the first day of radiotherapy and three months after radiotherapy, there was a significant difference in patients’ physical function average (p= 0.049), future expectation (p= 0.033), sexual life (p= 0.029), sexual satisfaction (p< 0.001), and hair loss (p= 0.011), and arm related problems (p< 0.001). According to the analysis of variance in repeated measurements, physical function, sexual life, side effects, hair loss, dyspnea, and future expectation were statistically significant according to the type of surgery, and for hormone therapy, sexual life, hair loss, constipation and financial difficulty were found statistically significant. Conclusion: It was observed that other than radiotherapy, hormone therapy and surgical techniques were also effective on the quality of life in patients receiving radiotherapy for breast cancer.

  • Open Access

    Autophagy-related genes affect the survival of multiple myeloma patients depending on chromosomal abnormality

    by Gizem Ayna Duran, Yasemin Benderli Cihan

    Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status. Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN. Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan–Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways. Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A , FKBP1B , FOXO3 , and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering. Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.